StockNews.AI
COLL
StockNews.AI
187 days

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

1. Collegium Pharmaceutical to report Q4 and full-year 2024 results on February 27. 2. Conference call scheduled post-financial results for detailed discussion. 3. Company focuses on pain management and ADHD treatment expansion. 4. Jornay PM acquisition enhances Collegium's neuropsychiatry portfolio. 5. Strategic growth aims for disciplined capital deployment.

3m saved
Insight
Article

FAQ

Why Bullish?

The upcoming earnings report and expansion strategy could positively influence investor perception, similar to previous quarters where strong earnings correlated with stock price increases.

How important is it?

Earnings reports are key for investors, influencing stock price through revealed performance indicators.

Why Short Term?

The earnings report on February 27 is imminent, with potential immediate effects on stock price reflective of financial performance.

Related Companies

JORNPM
February 13, 2025 08:00 ET  | Source: Collegium Pharmaceutical, Inc. STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 2024 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event. About Collegium Pharmaceutical, Inc.Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com. Investor Contact: Danielle JesseDirector, Investor Relationsir@collegiumpharma.com Media Contact:Cheryl WheelerHead of Corporate Communicationscommunications@collegiumpharma.com

Related News